CN105073766A - 取代的核苷、核苷酸及其类似物 - Google Patents

取代的核苷、核苷酸及其类似物 Download PDF

Info

Publication number
CN105073766A
CN105073766A CN201380072742.9A CN201380072742A CN105073766A CN 105073766 A CN105073766 A CN 105073766A CN 201380072742 A CN201380072742 A CN 201380072742A CN 105073766 A CN105073766 A CN 105073766A
Authority
CN
China
Prior art keywords
compound
alkyl
replaced
optional
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380072742.9A
Other languages
English (en)
Chinese (zh)
Inventor
莱昂尼德·贝格尔曼
王广义
大卫·伯纳德·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biopharma Inc
Original Assignee
Alios Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc filed Critical Alios Biopharma Inc
Priority to CN201910638928.5A priority Critical patent/CN110684067A/zh
Publication of CN105073766A publication Critical patent/CN105073766A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201380072742.9A 2012-12-21 2013-12-19 取代的核苷、核苷酸及其类似物 Pending CN105073766A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910638928.5A CN110684067A (zh) 2012-12-21 2013-12-19 取代的核苷和核苷酸

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261745466P 2012-12-21 2012-12-21
US61/745,466 2012-12-21
US201361890125P 2013-10-11 2013-10-11
US61/890,125 2013-10-11
PCT/US2013/076740 WO2014100505A1 (en) 2012-12-21 2013-12-19 Substituted nucleosides, nucleotides and analogs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910638928.5A Division CN110684067A (zh) 2012-12-21 2013-12-19 取代的核苷和核苷酸

Publications (1)

Publication Number Publication Date
CN105073766A true CN105073766A (zh) 2015-11-18

Family

ID=50975302

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380072742.9A Pending CN105073766A (zh) 2012-12-21 2013-12-19 取代的核苷、核苷酸及其类似物
CN201910638928.5A Pending CN110684067A (zh) 2012-12-21 2013-12-19 取代的核苷和核苷酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910638928.5A Pending CN110684067A (zh) 2012-12-21 2013-12-19 取代的核苷和核苷酸

Country Status (31)

Country Link
US (12) US9249174B2 (enExample)
EP (3) EP2935303B1 (enExample)
JP (4) JP6284547B2 (enExample)
KR (4) KR102327888B1 (enExample)
CN (2) CN105073766A (enExample)
AP (1) AP2015008533A0 (enExample)
AU (3) AU2013361200A1 (enExample)
BR (1) BR112015014457A2 (enExample)
CA (1) CA2894542C (enExample)
CL (2) CL2015001699A1 (enExample)
CY (1) CY1124742T1 (enExample)
DK (1) DK2935303T3 (enExample)
EA (1) EA201590943A1 (enExample)
EC (1) ECSP15031144A (enExample)
ES (1) ES2865402T3 (enExample)
GE (1) GEP201706757B (enExample)
HR (1) HRP20210510T1 (enExample)
HU (1) HUE053946T2 (enExample)
IL (3) IL296551B2 (enExample)
LT (1) LT2935303T (enExample)
MX (1) MX2015007925A (enExample)
PE (1) PE20151433A1 (enExample)
PH (1) PH12015501423A1 (enExample)
PL (1) PL2935303T3 (enExample)
PT (1) PT2935303T (enExample)
RS (1) RS61767B1 (enExample)
SG (2) SG11201504554UA (enExample)
SI (1) SI2935303T1 (enExample)
SM (1) SMT202100259T1 (enExample)
TW (2) TW201900182A (enExample)
WO (1) WO2014100505A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105307662A (zh) * 2013-05-16 2016-02-03 里博科学有限责任公司 4’-氟-2’-甲基取代的核苷衍生物
CN106083773A (zh) * 2016-05-31 2016-11-09 杭州惠诺医药科技有限公司 3,5‑二苯甲酰基‑2‑去氧‑2‑氟‑2‑甲基‑D‑核糖‑γ‑内酯的制备方法
CN107337702A (zh) * 2016-04-29 2017-11-10 江苏豪森药业集团有限公司 结晶型hcv抑制剂及其制备方法和应用
WO2019237297A1 (en) * 2018-06-14 2019-12-19 Janssen Pharmaceuticals, Inc. Processes for preparing compounds/intermediates useful in the treatment of viral infections
CN111194217A (zh) * 2017-09-21 2020-05-22 里伯赛恩斯有限责任公司 作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物
US10953030B2 (en) 2013-05-16 2021-03-23 Riboscience Llc 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
CN113234102A (zh) * 2021-05-18 2021-08-10 宁波大学 一种三配位磷衍生物及中间体及制备方法

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2480559T3 (da) 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
MA34470B1 (fr) 2010-07-22 2013-08-01 Gilead Sciences Inc Procédés et composés pour traiter des infections à virus paramyxoviridae
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
SI2794627T1 (sl) 2011-12-22 2019-02-28 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
PL2861611T3 (pl) 2012-05-25 2017-08-31 Janssen Sciences Ireland Uc Nukleozydy uracylowe spirooksetanu
EP2935305A4 (en) 2012-12-21 2016-08-03 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
ES2865402T3 (es) * 2012-12-21 2021-10-15 Janssen Biopharma Inc 4'-fluoronucleósidos, 4'-fluoronucleótidos y análogos de los mismos para el tratamiento del VHC
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
CA2908313A1 (en) 2013-04-05 2014-10-09 Alios Biopharma, Inc. Hepatitis c viral infection treatment using a combination of compounds
TWI655199B (zh) 2013-06-26 2019-04-01 美商艾洛斯生物製藥公司 經取代之核苷、核苷酸及其類似物
EP3013340B9 (en) 2013-06-26 2023-10-04 Janssen Pharmaceuticals, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3054616B1 (en) * 2013-10-04 2018-04-18 LG Electronics Inc. Method whereby terminal transmits ack/nack in wireless communication system, and device therefor
JP6562908B2 (ja) 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
PH12016501567B1 (en) 2014-02-06 2023-12-06 Riboscience Llc 4`-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
EP3157915B1 (en) 2014-06-17 2019-02-27 Pfizer Inc Substituted dihydroisoquinolinone compounds
AU2015280248B2 (en) 2014-06-24 2021-04-08 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ727582A (en) 2014-06-24 2018-06-29 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CA2952812A1 (en) * 2014-06-24 2015-12-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
WO2016069489A1 (en) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CN104478976A (zh) * 2014-11-12 2015-04-01 苏州明锐医药科技有限公司 索非布韦的制备方法
MA41441A (fr) * 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
WO2016134054A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
CN107427530B (zh) 2015-03-06 2020-09-08 阿堤亚制药公司 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸
MX383931B (es) 2015-03-11 2025-03-14 Janssen Biopharma Inc Compuestos de aza-piridona y usos de estos.
CN106146433B (zh) * 2015-03-26 2019-04-26 常州制药厂有限公司 一种索非布韦的中间体的制备方法
EP3344642A1 (en) 2015-09-02 2018-07-11 AbbVie Inc. Anti-viral tetrahydrofurane derivatives
MX394858B (es) 2015-09-16 2025-03-24 Gilead Sciences Inc Compuestos de formula i para usarse en el tratamiento de infecciones por virus arenaviridae y coronaviridae
US9988416B2 (en) 2016-03-24 2018-06-05 Novartis Ag Alkynyl nucleoside analogs as inhibitors of human rhinovirus
US11192914B2 (en) * 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018017989A1 (en) * 2016-07-22 2018-01-25 Janssen Pharmaceuticals, Inc. Combination therapy regimen for treatment of selected hcv genotypes
WO2018031818A2 (en) 2016-08-12 2018-02-15 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2017324939B2 (en) 2016-09-07 2021-10-14 Atea Pharmaceuticals, Inc. 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment
US10519186B2 (en) 2017-02-01 2019-12-31 Atea Pharmaceuticals, Inc. Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
CA3056072C (en) 2017-03-14 2022-08-23 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
KR20190141747A (ko) 2017-05-01 2019-12-24 길리애드 사이언시즈, 인코포레이티드 (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
EP4512475A3 (en) 2017-07-11 2025-05-14 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
KR102822647B1 (ko) 2017-10-04 2025-06-19 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 그의 용도
RS66222B1 (sr) 2017-12-07 2024-12-31 Univ Emory N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim
KR20200140274A (ko) * 2018-03-07 2020-12-15 에모리 유니버시티 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도
KR20200140865A (ko) 2018-04-10 2020-12-16 아테아 파마슈티컬즈, 인크. 간경변증을 갖는 hcv 감염 환자의 치료
US20220220145A1 (en) * 2019-04-22 2022-07-14 Ligand Pharmaceuticals, Inc. Cyclic phosphate compounds
CN114375296A (zh) * 2019-06-06 2022-04-19 艾维迪提生物科学公司 核酸多肽组合物及其用途
EP3999519A4 (en) 2019-07-17 2023-08-16 Nucorion Pharmaceuticals, Inc. CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS
WO2021140471A1 (en) * 2020-01-10 2021-07-15 Janssen Biopharma, Inc. Method for synthesis of 2'-alkyl- or 2'-alkenyl- or 2'-alkynyl-4'-fluoro-adenosine derivatives and intermediates thereof
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
JP7664287B2 (ja) 2020-05-29 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド レムデシビル治療方法
AU2021296841B2 (en) 2020-06-24 2025-01-23 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物及びその使用
KR20250111239A (ko) 2020-08-27 2025-07-22 길리애드 사이언시즈, 인코포레이티드 바이러스 감염 치료를 위한 화합물 및 방법
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
KR20230170745A (ko) 2021-04-16 2023-12-19 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
CN117500494A (zh) 2021-06-17 2024-02-02 阿堤亚制药公司 有利的抗hcv联合疗法
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CA3244278A1 (en) 2022-03-02 2023-09-07 Gilead Sciences Inc COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
CN116947947A (zh) 2022-04-20 2023-10-27 中国科学院上海药物研究所 抗病毒核苷类似物及其药物组合物和用途
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816558A (zh) * 2003-05-30 2006-08-09 法莫赛特股份有限公司 修饰的氟化核苷类似物
CN101918425A (zh) * 2007-03-30 2010-12-15 法莫赛特股份有限公司 核苷氨基磷酸酯前药
CN102119167A (zh) * 2008-06-11 2011-07-06 法莫赛特股份有限公司 核苷环状磷酸酯
WO2012088155A1 (en) * 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
WO2013092481A1 (en) * 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
CN105307662A (zh) * 2013-05-16 2016-02-03 里博科学有限责任公司 4’-氟-2’-甲基取代的核苷衍生物

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US112966A (en) * 1871-03-21 Improvement in hay and cotton-presses
US3817978A (en) 1971-06-16 1974-06-18 Syntex Inc 4-fluoro nucleosides and sugar intermediates, and methods of preparing
US3852267A (en) 1972-08-04 1974-12-03 Icn Pharmaceuticals Phosphoramidates of 3{40 ,5{40 -cyclic purine nucleotides
DE3239986A1 (de) 1982-10-28 1984-05-03 Robert Bosch Gmbh, 7000 Stuttgart Handwerkzeugmaschine mit einem kreisscheibenfoermigen werkzeug
US4713383A (en) 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5679342A (en) 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
IN167775B (enExample) 1988-06-24 1990-12-22 Hoechst India
US6027729A (en) 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
DE3932052A1 (de) 1989-09-26 1991-04-04 Basf Ag Oxazol- bzw. thiazolcarbonsaeureamide
MY106399A (en) 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
JP2889408B2 (ja) 1991-09-17 1999-05-10 富士写真フイルム株式会社 アゾメチン化合物及びこれを含有する熱転写色素供与材料
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
AU729657B2 (en) 1992-05-11 2001-02-08 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
DE4232852A1 (de) 1992-09-30 1994-03-31 Bayer Ag Imidazolinyl-pyridazine
ZA943999B (en) 1993-06-09 1995-02-03 Lonza Ag Quaternary ammonium and waterproofing/preservative compositions
AU7661594A (en) 1993-09-22 1995-04-10 Glaxo Wellcome House Bis(amidinobenzimidazolyl)alkanes as antiviral agents
DE4341161A1 (de) 1993-12-02 1995-06-08 Michael Prof Dr Zeppezauer Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese
JPH07242544A (ja) 1994-03-01 1995-09-19 Takeda Chem Ind Ltd 抗腫瘍剤
RU2186569C2 (ru) 1996-01-23 2002-08-10 Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах
CA2267279A1 (en) 1996-10-16 1998-04-23 Devron Averett Monocyclic l-nucleosides, analogs and uses thereof
CA2266889A1 (en) 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof
ATE293123T1 (de) 1997-09-12 2005-04-15 Exiqon As Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US6348587B1 (en) 1998-02-25 2002-02-19 Emory University 2′-Fluoronucleosides
US20030203862A1 (en) 1998-03-26 2003-10-30 Miraglia Loren J. Antisense modulation of MDM2 expression
WO1999061583A2 (en) 1998-05-28 1999-12-02 Incara Pharmaceuticals Corp. Carbohydrate-based scaffold compounds, combinatorial libraries and methods for their construction
DE19855963A1 (de) 1998-12-04 2000-06-08 Herbert Schott Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
CA2372085C (en) 1999-05-04 2009-10-27 Exiqon A/S L-ribo-lna analogues
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2001272923A1 (en) 2000-05-26 2001-12-11 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
GB0019124D0 (en) 2000-08-03 2000-09-27 Pfizer Novel process
EP1411954B1 (en) 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
JP2004532184A (ja) 2001-01-22 2004-10-21 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
EP1438054A4 (en) 2001-09-28 2006-07-26 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
AT411065B (de) 2001-12-27 2003-09-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von heterocyclischen (r)- und (s)-cyanhydrinen
US7323453B2 (en) 2002-02-13 2008-01-29 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
US20120041184A1 (en) 2002-02-20 2012-02-16 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2005524662A (ja) 2002-02-28 2005-08-18 ビオタ インコーポレーティッド ヌクレオシド５’−一リン酸模倣物およびこれらのプロドラッグ
AU2003237249A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
EP1572945A2 (en) 2002-06-27 2005-09-14 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CA2490191C (en) 2002-06-28 2010-08-03 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside prodrugs for treating flaviviridae infections
WO2004007512A2 (en) 2002-07-16 2004-01-22 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003259735A1 (en) 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US7393954B2 (en) 2002-12-12 2008-07-01 Reliable Biopharmaceutical Corporation Process for the production of pentostatin aglycone and pentostatin
AU2003225705A1 (en) 2003-03-07 2004-09-30 Ribapharm Inc. Cytidine analogs and methods of use
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
WO2004092144A2 (en) 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag Quinazoline compounds useful as p38 kinase inhibitors
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020884A2 (en) * 2003-05-14 2005-03-10 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
US7507859B2 (en) 2003-06-16 2009-03-24 Fifth Base Llc Functional synthetic molecules and macromolecules for gene delivery
KR20060084845A (ko) 2003-07-25 2006-07-25 이데닉스 (케이만) 리미티드 Ｃ형 간염을 포함하는 플라비비리다에를 치료하기 위한퓨린 뉴클레오시드 유사체
KR20060123707A (ko) 2003-08-27 2006-12-04 바이오타, 인코포레이티드 치료제로서의 신규 트리시클릭 뉴클레오시드 또는뉴클레오티드
CA2542077A1 (en) 2003-10-08 2005-04-21 President And Fellows Of Harvard College Pyrovalerone analogs and therapeutic uses thereof
RU2007102281A (ru) 2004-06-23 2008-07-27 Айденикс (Кайман) Лимитед (Ky) 5-аза-7-деазапуриновые производные для лечения заболеваний, связанных с flaviviridae
US20070265222A1 (en) 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
EP1828217A2 (en) 2004-12-16 2007-09-05 Febit Biotech GmbH Polymerase-independent analysis of the sequence of polynucleotides
CA2600886A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
US20100279974A1 (en) 2005-03-09 2010-11-04 Claire Pierra Nucleosides With Non-Natural Bases as Anti-Viral Agents
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
EP1877054A2 (en) 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006116512A1 (en) 2005-04-26 2006-11-02 The Board Of Trustees Of The University Of Illinois, Urbana, Il Nucleoside compounds and methods of use thereof
CN101287472B (zh) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
WO2007113538A1 (en) 2006-04-03 2007-10-11 Astrazeneca Ab Substituted adenines and the uses thereof
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
DE602007011658D1 (de) 2006-10-10 2011-02-10 Medivir Ab Hcv-nukleosidinhibitor
WO2008089439A2 (en) 2007-01-18 2008-07-24 Fred Hutchinson Cancer Research Center Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
AU2008210411A1 (en) 2007-01-31 2008-08-07 Alios Biopharma, Inc. 2-5A derivatives and their use as anti-cancer, anti-viral and anti-parasitic agents
JP2008214305A (ja) 2007-03-07 2008-09-18 Kotobuki Seiyaku Kk 置換アミン誘導体及びこれを有効成分とする医薬組成物
WO2008117047A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolo[3, 4-d]pyrimidine derivatives as antibacterial compounds
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
EP1980568A1 (de) 2007-04-13 2008-10-15 Eberhard Karls Universität Tübingen Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung
PL2014771T3 (pl) 2007-06-25 2015-05-29 Anadys Pharmaceuticals Inc Ciągły proces hydrolizy enzymatycznej
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
EP2019100A1 (en) 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
WO2009058800A2 (en) 2007-10-29 2009-05-07 President And Fellows Of Harvard College Synthesis of nucleosides
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8293720B2 (en) 2007-12-20 2012-10-23 Dogwood Pharmaceuticals, Inc. Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
WO2009086201A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents
WO2009086192A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
PE20091492A1 (es) 2008-02-22 2009-10-22 Irm Llc Compuestos y composiciones como inhibidores de c-kit y de la cinasa pdgfr
CA2722308C (en) 2008-04-15 2024-02-27 Rfs Pharma, Llc. Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
US20110171192A1 (en) 2008-09-05 2011-07-14 Hiroshi Tomiyama Substituted amine derivative and medicinal composition comprising same as the active ingredient
TW201023858A (en) 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
CN102753563A (zh) 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
BRPI1005401A2 (pt) 2009-02-06 2019-04-02 Rfs Pharma, Llc pro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
AP2011005929A0 (en) 2009-03-20 2011-10-31 Alios Biopharma Inc Substituted nucleoside and nucleotide analogs.
US20100240604A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
EP2264169A1 (en) 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
US20100331397A1 (en) 2009-06-24 2010-12-30 Alios Biopharma, Inc. 2-5a analogs and their methods of use
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
ES2614932T3 (es) * 2009-09-29 2017-06-02 Janssen Products, L.P. Derivados de fosforoamidatos de nucleósidos
WO2011057204A2 (en) 2009-11-06 2011-05-12 The Johns Hopkins University Lrrk2-mediated neuronal toxicity
CA2794018C (en) 2010-03-24 2016-05-10 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
FR2960235B1 (fr) 2010-05-18 2013-11-01 Inst Francais Du Petrole Procede d'oligomerisation des olefines utilisant une composition comprenant un complexe organometallique contenant un ligand alcoxy fonctionnalise par un hetero-atome.
FR2960234B1 (fr) 2010-05-18 2013-11-01 Inst Francais Du Petrole Procede de dimerisation de l'ethylene en butene-1 utilisant une composition comprenant un complexe a base de titane et un ligand alcoxy fonctionnalise par un hetero-atome.
PH12013500033A1 (en) 2010-07-19 2017-07-26 Gilead Sciences Inc Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
MA34470B1 (fr) 2010-07-22 2013-08-01 Gilead Sciences Inc Procédés et composés pour traiter des infections à virus paramyxoviridae
WO2012016713A1 (en) 2010-08-05 2012-02-09 Ruprecht-Karls-Universität Heidelberg Tumour targeting with polypeptides
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
SG188497A1 (en) 2010-09-22 2013-05-31 Alios Biopharma Inc Substituted nucleotide analogs
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
AR083221A1 (es) 2010-09-29 2013-02-06 Univ Nac Quilmes Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato
US20120082795A1 (en) 2010-10-01 2012-04-05 Ppg Industries Ohio, Inc. Method for using a primer comprising a self-emulsified polyester microgel
WO2012074547A2 (en) 2010-11-29 2012-06-07 New York University STEROID COMPOUNDS AS RORγt MODULATORS AND USES THEREOF
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
US9289445B2 (en) 2011-01-20 2016-03-22 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
US20120219568A1 (en) 2011-02-24 2012-08-30 Zhejiang University Epidithiodioxopiprazines and uses thereof in treating cancer
EA201391519A1 (ru) 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
EP2697241B1 (en) 2011-04-13 2019-06-12 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
WO2012167133A2 (en) 2011-06-01 2012-12-06 The Regents Of The University Of California Inhibitors of anandamide transport and their therapeutic uses
FR2977586B1 (fr) 2011-07-08 2013-07-12 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
DE102011108874A1 (de) 2011-07-28 2013-01-31 Hydac System Gmbh Steuervorrichtung
RU2640582C2 (ru) 2011-08-01 2018-01-10 Мбс Фарма, Инк. Производные витамина в6 нуклеотидов, ациклических нуклеотидов и ациклических нуклеозидных фосфонатов
WO2013044030A1 (en) * 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
CN103102345B (zh) 2011-11-14 2015-06-03 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
FR2982858B1 (fr) 2011-11-18 2013-11-29 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
FR2984322B1 (fr) 2011-12-16 2013-12-20 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
SI2794627T1 (sl) 2011-12-22 2019-02-28 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
WO2013138210A1 (en) 2012-03-14 2013-09-19 Ning Xi Substituted cyclic compounds and methods of use
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2828278A4 (en) 2012-03-21 2015-12-09 Alios Biopharma Inc PROCESSES FOR PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS
ME03502B (me) 2012-03-21 2020-04-20 Janssen Biopharma Inc Supstituisani nukleozidi, nukleotidi i njihovi analozi
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
CN104470939B (zh) * 2012-05-22 2017-04-26 埃迪尼克斯医药有限责任公司 用于肝脏疾病的d型氨基酸化合物
EP2676987A1 (en) 2012-06-21 2013-12-25 Universidad De Burgos Cross-linked aramid
EP2870169A1 (en) 2012-07-03 2015-05-13 Bristol-Myers Squibb Company Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
JP6243908B2 (ja) 2012-08-23 2017-12-06 アリオス バイオファーマ インク． パラミクソウイルス感染症を治療するための化合物
WO2014047117A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Process for preparing phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
JP6666147B2 (ja) 2012-09-26 2020-03-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 環状エーテルピラゾール−４−イル−ヘテロシクリル−カルボキサミド化合物と使用方法
MX362855B (es) 2012-09-26 2019-02-20 Merck Patent Gmbh Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
WO2014070771A1 (en) 2012-10-29 2014-05-08 Rfs Pharma, Llc Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
EP2935304A1 (en) * 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
WO2014100425A1 (en) 2012-12-20 2014-06-26 Aldexa Therapeutics, Inc. Peri-carbinols
EP2935305A4 (en) 2012-12-21 2016-08-03 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF
ES2718495T3 (es) 2012-12-21 2019-07-02 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
MY199894A (en) 2012-12-21 2023-11-27 Epizyme Inc Prmt5 inhibitors and uses thereof
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
HUE039848T2 (hu) 2012-12-21 2019-02-28 Hoffmann La Roche Peptidek oxitocin agonistákként
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
PE20151280A1 (es) 2012-12-21 2015-09-12 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
ES2865402T3 (es) 2012-12-21 2021-10-15 Janssen Biopharma Inc 4'-fluoronucleósidos, 4'-fluoronucleótidos y análogos de los mismos para el tratamiento del VHC
LT2934567T (lt) 2012-12-21 2018-09-10 Sanofi Eksendino-4 dariniai kaip dvigubi glp1/gip arba trigubi glp1/gip/gliukagono agonistai
LU92126B1 (fr) 2012-12-31 2014-07-01 Cesa Alliance Sa Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US9675070B2 (en) * 2013-03-04 2017-06-13 Bayer Cropscience Aktiengesellschaft Halogen-substituted compounds
US20140309413A1 (en) 2013-03-11 2014-10-16 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
CA2908313A1 (en) 2013-04-05 2014-10-09 Alios Biopharma, Inc. Hepatitis c viral infection treatment using a combination of compounds
TWI655199B (zh) 2013-06-26 2019-04-01 美商艾洛斯生物製藥公司 經取代之核苷、核苷酸及其類似物
EP3013340B9 (en) 2013-06-26 2023-10-04 Janssen Pharmaceuticals, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ716822A (en) 2013-08-21 2017-10-27 Alios Biopharma Inc Antiviral compounds
KR102286860B1 (ko) 2013-09-12 2021-08-05 얀센 바이오파마, 인코퍼레이트. 피리다지논 화합물 및 이의 용도
KR102323515B1 (ko) 2013-09-12 2021-11-05 얀센 바이오파마, 인코퍼레이트. 아자-피리돈 화합물 및 이의 용도
JP6562908B2 (ja) * 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
AU2015280248B2 (en) 2014-06-24 2021-04-08 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ727582A (en) 2014-06-24 2018-06-29 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
JP2017525681A (ja) 2014-07-22 2017-09-07 アリオス バイオファーマ インク． パラミクソウイルスの治療方法
SG11201700851WA (en) 2014-08-05 2017-03-30 Alios Biopharma Inc Combination therapy for treating a paramyxovirus
WO2016069489A1 (en) 2014-10-28 2016-05-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
MX383931B (es) 2015-03-11 2025-03-14 Janssen Biopharma Inc Compuestos de aza-piridona y usos de estos.
AU2017231824B2 (en) 2016-03-09 2021-07-01 Alios Biopharma, Inc. Acyclic antivirals
WO2017156407A1 (en) 2016-03-10 2017-09-14 Alios Biopharma, Inc. Method of preparing aza-pyridone compounds
WO2017223231A1 (en) 2016-06-21 2017-12-28 Alios Biopharma, Inc. (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza
US20180117042A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection
WO2018222774A1 (en) 2017-05-30 2018-12-06 Alios Biopharma, Inc. Methods for treating pneumoviruses
AU2019397582A1 (en) 2018-12-12 2021-06-10 Janssen Biopharma, Inc. Cyclobutyl nucleoside analogs as anti-virals
CA3122410A1 (en) 2018-12-12 2020-06-18 Janssen Biopharma, Inc. Cyclopentyl nucleoside analogs as anti-virals

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816558A (zh) * 2003-05-30 2006-08-09 法莫赛特股份有限公司 修饰的氟化核苷类似物
CN101918425A (zh) * 2007-03-30 2010-12-15 法莫赛特股份有限公司 核苷氨基磷酸酯前药
CN102119167A (zh) * 2008-06-11 2011-07-06 法莫赛特股份有限公司 核苷环状磷酸酯
WO2012088155A1 (en) * 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
WO2013092481A1 (en) * 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
CN105307662A (zh) * 2013-05-16 2016-02-03 里博科学有限责任公司 4’-氟-2’-甲基取代的核苷衍生物

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953030B2 (en) 2013-05-16 2021-03-23 Riboscience Llc 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
CN105307662B (zh) * 2013-05-16 2019-06-04 里博科学有限责任公司 4’-氟-2’-甲基取代的核苷衍生物
CN105307662A (zh) * 2013-05-16 2016-02-03 里博科学有限责任公司 4’-氟-2’-甲基取代的核苷衍生物
CN107337702A (zh) * 2016-04-29 2017-11-10 江苏豪森药业集团有限公司 结晶型hcv抑制剂及其制备方法和应用
CN107337702B (zh) * 2016-04-29 2021-11-05 江苏豪森药业集团有限公司 结晶型hcv抑制剂及其制备方法和应用
CN106083773A (zh) * 2016-05-31 2016-11-09 杭州惠诺医药科技有限公司 3,5‑二苯甲酰基‑2‑去氧‑2‑氟‑2‑甲基‑D‑核糖‑γ‑内酯的制备方法
CN106083773B (zh) * 2016-05-31 2019-06-14 杭州惠诺医药科技有限公司 3,5-二苯甲酰基-2-去氧-2-氟-2-甲基-D-核糖-γ-内酯的制备方法
CN111194217A (zh) * 2017-09-21 2020-05-22 里伯赛恩斯有限责任公司 作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物
US10682369B2 (en) 2017-09-21 2020-06-16 Riboscience Llc 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
US11351186B2 (en) 2017-09-21 2022-06-07 Riboscience Llc 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
CN111194217B (zh) * 2017-09-21 2024-01-12 里伯赛恩斯有限责任公司 作为hcv rna复制抑制剂的4’-氟-2’-甲基取代的核苷衍生物
WO2019237297A1 (en) * 2018-06-14 2019-12-19 Janssen Pharmaceuticals, Inc. Processes for preparing compounds/intermediates useful in the treatment of viral infections
CN113234102A (zh) * 2021-05-18 2021-08-10 宁波大学 一种三配位磷衍生物及中间体及制备方法

Also Published As

Publication number Publication date
KR102327888B1 (ko) 2021-11-17
LT2935303T (lt) 2021-03-25
ES2865402T3 (es) 2021-10-15
IL274901A (en) 2020-07-30
HUE053946T2 (hu) 2021-08-30
KR20210141773A (ko) 2021-11-23
EP2935303A1 (en) 2015-10-28
CY1124742T1 (el) 2022-07-22
CL2015001699A1 (es) 2015-10-30
SG11201504554UA (en) 2015-07-30
US9249174B2 (en) 2016-02-02
EP3912984A1 (en) 2021-11-24
US20230167151A1 (en) 2023-06-01
AU2018203337B2 (en) 2019-12-05
US20160024136A1 (en) 2016-01-28
AU2020200499A1 (en) 2020-02-13
US20140179910A1 (en) 2014-06-26
US20170037077A1 (en) 2017-02-09
PL2935303T3 (pl) 2021-10-04
KR20150100806A (ko) 2015-09-02
PE20151433A1 (es) 2015-10-16
JP6637023B2 (ja) 2020-01-29
TWI641615B (zh) 2018-11-21
ECSP15031144A (es) 2015-11-30
IL296551B2 (en) 2024-04-01
US12173025B2 (en) 2024-12-24
US11485753B2 (en) 2022-11-01
TW201429983A (zh) 2014-08-01
SG10201802325TA (en) 2018-04-27
IL274901B2 (en) 2023-02-01
JP2022180507A (ja) 2022-12-06
IL274901B (en) 2022-10-01
US20140179627A1 (en) 2014-06-26
US10487104B2 (en) 2019-11-26
BR112015014457A2 (pt) 2017-11-21
AU2018203337A1 (en) 2018-05-31
EP3421482A1 (en) 2019-01-02
CL2017001769A1 (es) 2018-02-16
US10112966B2 (en) 2018-10-30
HRP20210510T1 (hr) 2021-05-14
IL239324A0 (en) 2015-07-30
US10683320B2 (en) 2020-06-16
KR102168621B1 (ko) 2020-10-22
AP2015008533A0 (en) 2015-06-30
KR102788773B1 (ko) 2025-03-28
MX2015007925A (es) 2015-10-05
SMT202100259T1 (it) 2021-07-12
KR20200120776A (ko) 2020-10-21
IL239324B (en) 2020-11-30
US20160016987A1 (en) 2016-01-21
IL296551A (en) 2022-11-01
KR20230069261A (ko) 2023-05-18
EP2935303B1 (en) 2021-02-17
US10793591B2 (en) 2020-10-06
GEP201706757B (en) 2017-10-25
AU2020200499B2 (en) 2021-05-06
IL296551B1 (en) 2023-12-01
HK1216536A1 (en) 2016-11-18
WO2014100505A1 (en) 2014-06-26
SI2935303T1 (sl) 2021-08-31
TW201900182A (zh) 2019-01-01
PH12015501423A1 (en) 2015-09-14
JP2016505595A (ja) 2016-02-25
DK2935303T3 (da) 2021-05-03
PT2935303T (pt) 2021-04-30
US20160039858A1 (en) 2016-02-11
EP2935303A4 (en) 2016-08-10
RS61767B1 (sr) 2021-05-31
EA201590943A1 (ru) 2016-01-29
US20190031703A1 (en) 2019-01-31
AU2013361200A1 (en) 2015-07-23
JP6284547B2 (ja) 2018-02-28
CA2894542A1 (en) 2014-06-26
JP2018080178A (ja) 2018-05-24
JP2020063284A (ja) 2020-04-23
CA2894542C (en) 2023-10-31
US20190085011A1 (en) 2019-03-21
US20170037075A1 (en) 2017-02-09
CN110684067A (zh) 2020-01-14
KR102532198B1 (ko) 2023-05-11
US9243022B2 (en) 2016-01-26
JP7196054B2 (ja) 2022-12-26
US10144755B2 (en) 2018-12-04
US20210139523A1 (en) 2021-05-13
US20200079813A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
US12173025B2 (en) Substituted nucleosides, nucleotides and analogs thereof
CN105829333A (zh) 取代的核苷、核苷酸及其类似物
HK40064928A (en) 4’-fluoro-nucleosides, 4’-fluoro-nucleotides and analogs thereof for the treatment of hcv
HK1216536B (en) 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151118